CRP and head and neck squamous cell carcinoma: As previous studies have implicated the early on-treatment neutrophil-to-lymphocyte ratio (NLR) as a biomarker for response and survival in ICI-treated R/M HNSCC [10, 11], we used the NLR as a benchmark for CRP’s prognostic performance.